Flag of the European Union EU Clinical Trials Register Help

Clinical trials for multiple sclerosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    631 result(s) found for: multiple sclerosis. Displaying page 24 of 32.
    «« First « Previous 20  21  22  23  24  25  26  27  28  Next» Last»»
    EudraCT Number: 2020-003231-19 Sponsor Protocol Number: ViRap Start Date*: Information not available in EudraCT
    Sponsor Name:The Children's Memorial Health Institute
    Full Title: Randomized, placebo-controlled, double-blind and double-dummy clinical trial comparing the safety, tolerability, and efficacy of vigabatrin and rapamycin in a preventive treatment of infants with T...
    Medical condition: Tuberous Sclerosis Complex Epilepsy Tumors associated with Tuberous Sclerosis Complex
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004100-22 Sponsor Protocol Number: OS440-3004 Start Date*: 2018-03-16
    Sponsor Name:Osmotica Pharmaceutical US LLC
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Mu...
    Medical condition: Spasticity in patients with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005929-89 Sponsor Protocol Number: CLOU064C12302 Start Date*: 2022-02-01
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) SI (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) HR (Trial now transitioned) EE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004174-40 Sponsor Protocol Number: P080503 Start Date*: 2009-03-06
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Imagerie de la démyélinisation dans la sclérose en plaques : une étude en tomographie à émission de positons (TEP) avec le 11C-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (11C-PIB)
    Medical condition: Groupe I: volontaires sains Groupe II: patients avec une sclérose en plaques d'évolution rémittente .
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012300 Demyelinating disease (excl multiple sclerosis) PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005947-22 Sponsor Protocol Number: SIPO20 Start Date*: 2021-11-17
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis
    Medical condition: Active progressive MS course after an initial relapse clinical course
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000236-16 Sponsor Protocol Number: IPX056-B06-03 Start Date*: 2007-05-28
    Sponsor Name:IMPAX Laboratories, Inc.
    Full Title: A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the Pharmacokinetics and Pharmacodynamics of IPX056 in Subjects with Establis...
    Medical condition: Established Spasticity Resulting from Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2010-023047-15 Sponsor Protocol Number: CC-4047-SSC-001 Start Date*: 2012-03-15
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2 Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC...
    Medical condition: systemic sclerosis associated with interstitial lung disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10025109 Lung involvement in systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) IT (Prematurely Ended) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-003706-33 Sponsor Protocol Number: 28821 Start Date*: 2009-03-24
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS
    Medical condition: Subjects with a first clinical demyelinating event (Clinically Isolated Syndrome (CIS)) at high risk of converting to Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) FI (Prematurely Ended) EE (Prematurely Ended) AT (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) NO (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) GR (Completed) FR (Completed) SE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003008-38 Sponsor Protocol Number: 105MS306 Start Date*: 2019-06-17
    Sponsor Name:Biogen Idec Research Limited
    Full Title: An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years f...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) FR (Completed) PT (Completed) BG (Trial now transitioned) HU (Trial now transitioned) BE (Completed) SK (Trial now transitioned) GR (Completed) DE (Completed) ES (Ongoing) HR (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023677-19 Sponsor Protocol Number: VITAD-2010 Start Date*: 2011-03-23
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: Bio-molecular effects of interferon-beta and d-vitamin association
    Medical condition: PATIENT WITH RRMS AND SPMS
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004403-37 Sponsor Protocol Number: TEAM-Studie Start Date*: 2006-02-27
    Sponsor Name:Universitätsklinikum Heidelberg
    Full Title: Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zu...
    Medical condition: Uveitis intermedia with inflammatory macula edema with or without associated Multiple Sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005394-31 Sponsor Protocol Number: 12/0219 Start Date*: 2014-04-01
    Sponsor Name:UCL
    Full Title: MS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis
    Medical condition: Mutliple Sclerosis (Secondary Progressive)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001730-26 Sponsor Protocol Number: 205756 Start Date*: 2017-10-30
    Sponsor Name:Orchard Therapeutics (Europe) Ltd
    Full Title: A single arm, open label, clinical study of cryopreserved autologous CD34+ cells transduced with lentiviral vector containing human ARSA cDNA OTL-200, for the treatment of early onset Metachromatic...
    Medical condition: Metachromatic Leukodystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10067609 Metachromatic leukodystrophy PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002178-22 Sponsor Protocol Number: 11-AVR-130 Start Date*: 2011-12-26
    Sponsor Name:Avanir Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in ...
    Medical condition: Central Neuropathic Pain in Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000957-30 Sponsor Protocol Number: 191622-117 Start Date*: 2012-08-28
    Sponsor Name:Allergan Ltd.
    Full Title: BOTOX® for the Treatment of Urinary Incontinence due to Neurogenic Detrusor Overactivity in Patients with Multiple Sclerosis
    Medical condition: Urinary incontinence due to neurogenic detrusor overactivity (NDO) resulting from multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007663-25 Sponsor Protocol Number: MRZ 92579-0738/1 Start Date*: 2008-11-17
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A Long-Term Open Label Extension Study to assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus.
    Medical condition: congenital idiopathic nystagmus and aquired nystagmus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029864 Nystagmus LLT
    9.1 10029867 Nystagmus congenital LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004822-15 Sponsor Protocol Number: GNC-401 Start Date*: 2020-05-18
    Sponsor Name:GeNeuro Innovation SAS
    Full Title: A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Re...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003684-32 Sponsor Protocol Number: ISTANT Start Date*: 2008-06-18
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: Integrilin plus stenting to avoid myocardial necrosis trial. Pilot Study
    Medical condition: patients with diffuse CAD undergoing percutaneous treatment on a native coronary vassel with planned implantation of 33 mm of DES with reference vessel diameter 2.25-4.0 mm.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10011076 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006997-27 Sponsor Protocol Number: CRAD001M2301 Start Date*: 2011-06-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC)
    Medical condition: This study will evaluate the antitumor activity of RAD001 versus placebo in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC).
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-001377-28 Sponsor Protocol Number: 27577 Start Date*: 2008-06-11
    Sponsor Name:Merck Serono International S.A.
    Full Title: Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of...
    Medical condition: Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061664 Autoimmune disorder LLT
    9.1 10025139 Lupus erythematosus systemic LLT
    9.1 10047888 Wegener's granulomatosis LLT
    9.1 10002817 Antiphospholipid syndrome LLT
    9.1 10040767 Sjogren's syndrome LLT
    9.1 10039073 Rheumatoid arthritis LLT
    9.1 10028245 Multiple sclerosis LLT
    9.1 10045228 Type I diabetes mellitus LLT
    9.1 10011401 Crohn's disease LLT
    9.1 10009900 Colitis ulcerative LLT
    9.1 10003827 Autoimmune hepatitis LLT
    9.1 10049046 Autoimmune thyroiditis LLT
    9.1 10003822 Autoimmune haemolytic anaemia NOS LLT
    9.1 10034697 Pernicious anemia LLT
    9.1 10028417 Myasthenia gravis LLT
    9.1 10018620 Goodpasture's syndrome LLT
    9.1 10018766 Guillain Barre syndrome LLT
    9.1 10043554 Thrombocytopenia LLT
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 20  21  22  23  24  25  26  27  28  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 15:11:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA